查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1850575

血液篩檢市場按檢測類型、技術、最終用戶、樣本類型和檢測模式分類－2025-2032年全球預測

Blood Screening Market by Test Type, Technology, End User, Sample Type, Testing Mode - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血液篩檢市場規模將達到 106.4 億美元，複合年成長率為 9.06%。

主要市場統計數據
基準年 2024 53.1億美元
預計年份：2025年 57.9億美元
預測年份：2032年 106.4億美元
複合年成長率 (%) 9.06%

權威的介紹文章，闡述了診斷、工作流程需求和監管期望如何相互交織，從而重塑整個醫療保健系統的血液篩檢策略。

血液篩檢領域正處於一個關鍵的十字路口，臨床需求、監管嚴格程度和技術能力正在融合，重新定義輸血安全和感染疾病監測的管理方式。診斷靈敏度和特異性的提高使得早期檢測成為可能，而實驗室工作流程的整合和自動化則縮短了周轉時間並減少了操作人員的差異。同時，人們對捐血者安全、新出現的病原體和供應鏈韌性的擔憂日益加劇，促使相關人員重新評估檢測流程和籌資策略。

醫療保健領導者如今必須平衡臨床績效與營運現實，例如人員配備限制、基礎設施約束以及在分散式環境中對結果進行標準化解讀的需求。同時，檢測平台的設計和部署也日益受到跨領域優先事項的影響，例如資料互通性、品管和成本控制。本書清楚地介紹了診斷方法、檢測模式和最終用戶環境如何相互作用，從而影響血液篩檢計畫中的實際決策，為理解這些因素奠定了基礎。

簡明說明，介紹正在重塑血液篩檢工作流程和醫療保健供應商參與的重要技術、監管和營運變革。

過去幾年，在技術創新和不斷變化的臨床需求的驅動下，血液篩檢領域發生了翻天覆地的變化。照護現場能力日趨成熟，減少了對中心實驗室特定快速篩檢需求的依賴；同時，實驗室平台也實現了更高的自動化程度和數據連接性，以滿足通量和可追溯性的需求。同時，分子診斷也從小眾應用轉向更廣泛的操作整合，從而能夠更準確地檢測病原體和識別變異株。

這種轉變也在改變採購行為和供應商合約模式。醫療系統越來越傾向於尋求不僅能提供診斷效能，還能提供生命週期支援、遠端監控以及與實驗室資訊系統無縫整合的解決方案。監管機構正在明確新檢測方法和平台的核准路徑，從而影響其推廣應用的時間表。展望未來，互通性和模組化將成為平台選擇的核心，因為醫療機構需要優先考慮靈活性，以適應新的威脅和不斷變化的篩檢方案。

分析和審查 2025 年美國實施的關稅調整對營運和採購的累積影響，以及相關人員如何適應。

包括美國2025年關稅調整在內的政策變化，為診斷相關人員的採購和供應鏈規劃帶來了新的考量。關稅調整凸顯了優先考慮區域製造、延長關鍵耗材前置作業時間以及實現供應商多元化以降低進口成本波動風險的籌資策略的重要性。這些政策也影響供應商的路線選擇和庫存策略，促使企業專注於總到岸成本，而不僅僅是單位成本。

在實踐中，實驗室管理人員和採購團隊採取的應對措施包括加強需求預測、調整補貨門檻，以及與供應商建立策略夥伴關係，從而實現在地化生產並達成優先分銷協議。下游影響也延伸至資本設備採購週期，各機構需要權衡前期投資和持續依賴耗材之間的利弊。總體而言，2025 年的關稅環境凸顯了敏捷的供應鏈管治、情境規劃以及能夠應對地緣政治和政策衝擊的合約條款的重要性。

本文從細分市場的觀點主導，細緻入微分析了測試類型、技術模式、最終用戶環境、樣本處理和測試方式如何影響診斷選擇和部署。

細分分析揭示了不同的臨床需求和業務環境如何驅動不同檢測類型、技術、最終用戶、樣本類型和檢測模式的採用模式。乙型肝炎、C型肝炎、愛滋病毒和梅毒的篩檢各自具有不同的敏感性、窗口期和確診檢測要求，這些因素都會影響演算法設計和複檢管道。因此，診斷平台必須使分析效能與確診追蹤和捐血者諮詢的實際需求相符。

化學冷光可提供高性能的訊號檢測，而流式細胞技術支援某些免疫測定的多參數分析。免疫檢測分為三種類型：化學冷光免疫檢測、酵素結合免疫吸附檢測法和免疫測量，每種類型在試劑穩定性、自動化適用性和成本方面各不相同。分子診斷包括等溫擴增、次世代定序和聚合酵素鏈鎖反應，每種技術在速度、靈敏度和資訊深度方面各有重點。最終使用者環境（血庫、診所、診斷實驗室或醫院）會影響工作流程的整合、人員能力和認證要求。檢體類型（包括血漿、血清和全血）會影響分析前處理和檢測方法的選擇，而檢測模式的選擇（實驗室檢測或照護現場）則決定了檢測的執行地點和結果的實施方式。這些細分視角為將臨床目標與合適的診斷方案相匹配提供了一個實用的框架。

戰略區域分析詳細說明了醫療保健基礎設施、管理體制和生產能力如何決定全球不同區域的血液篩檢優先事項

區域動態以獨特的方式影響技術採納、監管管道和籌資策略，這些方式反映了醫療基礎設施、政策重點和製造生態系統。在美洲，大型綜合醫療系統和集中式血液服務往往傾向於採用高通量實驗室平台和全面的品質框架。報銷機制和國家指南進一步指導篩檢演算法的實施和推廣。

歐洲、中東和非洲呈現異質性環境，監管協調工作與基礎建設能力有差異。有些市場重視嚴謹性和全程可追溯性，而有些市場則優先考慮經濟實惠且適用於資源有限環境的穩健解決方案。在亞太地區，實驗室網路的快速現代化、在地化生產能力的提升以及對分子診斷的投資正在加速先進平台的普及，尤其關注可擴展性和供應鏈本地化。了解這些區域差異有助於供應商和醫療機構調整其商業策略和實施計劃，使其與當地需求和監管實際情況相符。

聚焦企業洞察，闡述供應商如何透過平台創新、服務模式和策略夥伴關係實現差異化，並獲得長久的生存和市場認可。

血液篩檢公司之間的競爭動態涵蓋平台創新、試劑組合、服務模式和監管互動等多個面向。領先的供應商正透過投資自動化、數位化連接和檢測範圍來提升自身競爭力，以滿足高效能血庫和照護現場環境的需求。這些公司也在不斷完善售後服務，例如遠距離診斷支援、耗材管理和培訓項目，以提高客戶維繫並減少終端用戶的操作障礙。

隨著企業尋求加快檢驗流程並實現在地化生產，與臨床實驗室、學術中心和生產合作夥伴建立合作關係和共同開發安排變得越來越普遍。市場參與企業的策略重點領域包括更快的周轉時間、更少的樣本量需求以及增強的多重檢測能力，以整合檢測工作流程。能夠清楚展示臨床效用、運作可靠性和強大的售後支援的供應商更有可能獲得醫療機構和血液服務機構的長期採購承諾。

向經營團隊提出具體建議，以提高診斷靈活性、供應彈性、數位整合、員工準備度和協同檢驗，從而使篩檢專案能夠適應未來發展。

產業領導者應優先考慮一系列切實可行的措施，以平衡臨床卓越性、營運韌性和商業性靈活性。首先，在採購決策中融入模組化理念，選擇可逐步升級和具備多重檢測能力的平台，從而減少對供應商的長期鎖定，並隨著檢測需求的變化保持靈活性。其次，投資於供應鏈多元化和合約條款，以確保關鍵耗材的持續供應，同時抵禦地緣政治和關稅衝擊。

第三，我們正在加速實驗室資訊系統的數位化連接和整合，以提高結果可追溯性、品質監控以及各臨床站點間的互通性。第四，我們正在製定清晰的推廣藍圖，該路線圖結合了實驗室驗證、員工培訓和確認性檢測途徑，以在不影響安全性的前提下推廣新技術。最後，我們正在與公共衛生機構和捐助機構合作進行試驗計畫，以在實際環境中檢驗新的檢測通訊協定。這些舉措將有助於各機構管理風險、最佳化營運績效並長期維持篩檢品質。

我們採用透明的三管齊下的調查方法，結合相關人員訪談、監管指導審查和技術評估，為決策者提供可操作的見解。

本研究採用三角測量法，結合主要相關人員訪談、方案和監管指南審查以及系統性技術評估，得出可靠的結論。主要訪談對象包括實驗室主任、輸血醫學專業人員、採購負責人和診斷設備供應商，旨在了解實際限制、推廣應用促進因素和實施經驗。此外，還對官方監管指南、臨床檢驗報告和設備標籤進行了結構化審查，以檢驗性能聲明和管道要求，從而補充了這些定性資訊。

技術評估著眼於分析原則、運作特性以及跨平台類型的互通性。供應鏈分析則檢視了製造佈局、分銷管道以及對關稅敏感的採購依賴性，以了解風險因素。在整個過程中，所有證據都根據當地法規環境和典型的終端使用者營運模式進行了情境化處理。最終獲得的洞見被綜合提煉，旨在突出可操作的啟示，而非抽象的預測，從而為臨床、營運和商業相關人員的策略決策提供支持。

清晰、可操作的結論強調，以證據主導的採納、供應鏈韌性和數位化整合是永續血液篩檢計畫的支柱。

血液篩檢處於臨床需求和技術能力的交匯點，這要求相關人員做出審慎的選擇，以平衡分析能力和營運限制。新的工具和增強的連接性為縮短檢測視窗、簡化工作流程和提高可追溯性提供了契機，但成功應用取決於量身定做的實施策略，這些策略需反映當地的基礎設施、人員能力和供應鏈實際情況。因此，決策者應優先考慮兼具臨床價值和營運可行性的解決方案。

簡而言之，採取務實且基於證據的方法至關重要：檢驗平台在其預期用途範圍內的有效性，加強供應鏈管治以應對政策變化，並整合支持品質和互通性的數位化工作流程。如此一來，醫療機構和診斷服務提供者便可確保其血液篩檢系統不僅技術先進，而且具有彈性、可擴展性，並與病患安全目標緊密契合。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 將人工智慧驅動的預測分析整合到血液疾病篩檢工作流程中，以提高檢測準確性
  • 利用智慧型手機連接和遠端實驗室整合，擴大家用血液篩檢套件，用於個人健康監測。
  • 採用可同時檢測多種血液標記的多重免疫檢測，可提高診斷效率與通量。
  • 在農村和醫療資源匱乏地區，對照護現場血液篩檢設備的需求日益成長，以促進疾病的早期發現。
  • 開發用於輸血服務中血液傳播病原體全面篩檢的次世代定序平台
  • 監管政策的改變推動了新興市場血液篩檢標準的統一，簡化了全球檢測通訊協定。

第6章美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按檢測類型分類的血液篩檢市場

  • 乙型肝炎篩檢
  • 丙型肝炎篩檢
  • 愛滋病毒篩檢
  • 梅毒篩檢

9. 按技術分類的血液篩檢市場

  • 化學冷光
  • 流式細胞技術
  • 免疫檢測
    • 化學冷光免疫檢測
    • 酵素結合免疫吸附試驗
    • 免疫檢測
  • 分子診斷
    • 等溫擴增
    • 下一代定序
    • 聚合酵素鏈鎖反應

第10章 依最終用戶分類的血液篩檢市場

  • 血庫
  • 診所
  • 診斷實驗室
  • 醫院

第11章 依樣本類型分類的血液篩檢市場

  • 電漿
  • 血清
  • 全血

第12章 依檢測模式分類的血液篩檢市場

  • 實驗室
  • 照護現場

第13章 各地區血液篩檢市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 按組別分類的血液篩檢市場

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國血液篩檢市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Siemens Healthineers AG
    • Danaher Corporation
    • Thermo Fisher Scientific Inc.
    • Grifols, SA
    • Bio-Rad Laboratories, Inc.
    • Ortho Clinical Diagnostics, Inc.
    • Hologic, Inc.
    • Terumo BCT, Inc.
Product Code: MRR-374DB5A06BE3

The Blood Screening Market is projected to grow by USD 10.64 billion at a CAGR of 9.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.31 billion
Estimated Year [2025] USD 5.79 billion
Forecast Year [2032] USD 10.64 billion
CAGR (%) 9.06%

An authoritative introduction framing how diagnostics, workflow imperatives, and regulatory expectation intersect to reshape blood screening strategy across healthcare systems

The landscape of blood screening is at a pivotal juncture where clinical expectation, regulatory rigor, and technological capability converge to redefine how transfusion safety and infectious disease surveillance are managed. Advances in diagnostic sensitivity and specificity are enabling earlier detection windows, while integrated laboratory workflows and automation are reducing turnaround times and operator variability. These developments are occurring alongside heightened attention to donor safety, pathogen emergence, and supply chain resilience, prompting stakeholders to reassess testing algorithms and procurement strategies.

Healthcare leaders must now balance clinical performance with operational realities, including staffing limitations, infrastructure constraints, and the need for standardized result interpretation across decentralized settings. At the same time, the design and deployment of testing platforms are increasingly influenced by cross-disciplinary priorities such as data interoperability, quality management, and cost containment. In this context, a clear-eyed introduction lays the foundation for understanding how diagnostic modalities, testing modes, and end-user environments interact to shape practical decision-making in blood screening programs.

A concise exploration of pivotal technological, regulatory, and operational shifts that are reshaping blood screening workflows and supplier engagement across care settings

Over recent years the blood screening landscape has experienced transformative shifts driven by technological innovation and evolving clinical imperatives. Point-of-care capabilities have matured, reducing the dependence on centralized laboratories for certain rapid screening needs, while laboratory-based platforms have embraced higher degrees of automation and data connectivity to meet throughput and traceability demands. Concurrently, molecular diagnostics have moved from niche applications toward broader operational integration, enabling more precise pathogen detection and variant discrimination.

These shifts have also produced changes in procurement behavior and vendor engagement models. Health systems are increasingly seeking solutions that deliver not only diagnostic performance but also lifecycle support, remote monitoring, and seamless integration with laboratory information systems. Regulatory agencies are clarifying pathways for novel assays and platforms, which in turn affects adoption timelines. Looking ahead, interoperability and modularity will be central to platform selection as institutions prioritize flexibility to respond to emergent threats and evolving screening protocols.

An analytical review of the cumulative operational and procurement impacts generated by United States tariff adjustments enacted in 2025 and how stakeholders adapted

Policy changes, including tariff adjustments implemented in the United States in 2025, have introduced new considerations into procurement and supply chain planning for diagnostic stakeholders. Tariff realignment has increased the prominence of sourcing strategies that prioritize regional manufacturing, longer lead times for critical consumables, and diversification of supplier bases to mitigate exposure to import-related cost volatility. These measures also influenced vendor routing decisions and inventory policies, prompting a closer examination of total landed cost beyond unit pricing.

In practice, laboratory managers and procurement teams responded by enhancing demand forecasting, revising reorder thresholds, and engaging in strategic partnerships with suppliers capable of local production or preferential distribution agreements. The downstream impacts extended to capital equipment procurement cycles as organizations evaluated tradeoffs between upfront investment and recurring consumable dependencies. Overall, the 2025 tariff environment underscored the necessity for agile supply chain governance, scenario planning, and contractual provisions that address geopolitical and policy-driven disruptions.

A nuanced segmentation-driven perspective showing how test type, technology modality, end-user setting, sample handling, and testing mode jointly inform diagnostic selection and deployment

Segmentation analysis illuminates how differentiated clinical needs and operational contexts drive adoption patterns across test types, technologies, end users, sample types, and testing modes. Within test types, screening for Hepatitis B, Hepatitis C, HIV, and Syphilis each carries distinct sensitivity, window-period, and confirmatory testing implications that affect algorithm design and reflex testing pathways. Diagnostic platforms must therefore align analytical performance with practical requirements for confirmatory follow-up and donor counselling.

Technology segmentation further clarifies capability tradeoffs: chemiluminescence delivers high-throughput signal detection while flow cytometry supports multi-parametric analysis for certain immunologic assessments. Immunoassays span chemiluminescence immunoassay, enzyme linked immunosorbent assay, and radioimmunoassay formats, each presenting different reagent stability, automation compatibility, and cost profiles. Molecular diagnostics encompass isothermal amplification, next generation sequencing, and polymerase chain reaction methods, offering varying balances of speed, sensitivity, and information depth. End-user contexts-blood banks, clinics, diagnostic laboratories, and hospitals-shape workflow integration, staff competencies, and accreditation requirements. Sample type considerations including plasma, serum, and whole blood influence pre-analytical handling and test selection, while testing mode choices between lab-based and point-of-care approaches determine where testing occurs and how results are actioned operationally. Together, these segmentation lenses provide a practical framework for pairing clinical aims with appropriate diagnostic solutions.

A strategic regional analysis detailing how healthcare infrastructure, regulatory regimes, and manufacturing capacity drive divergent blood screening priorities across global regions

Regional dynamics influence technology adoption, regulatory pathways, and procurement strategies in distinct ways that reflect healthcare infrastructure, policy priorities, and manufacturing ecosystems. In the Americas, large integrated health systems and centralized blood services tend to favor high-throughput laboratory platforms and comprehensive quality frameworks, while also supporting innovation pilots that bridge laboratory and point-of-care testing for decentralized contexts. Reimbursement structures and national guidelines further guide how screening algorithms are implemented and scaled.

Europe, Middle East & Africa present a heterogeneous environment where regulatory harmonization efforts coexist with variable infrastructure capacities; some markets emphasize stringency and full traceability, whereas others prioritize affordable, robust solutions suited to constrained settings. In the Asia-Pacific region, rapid modernization of laboratory networks, local manufacturing capacity, and investments in molecular diagnostics are accelerating adoption of advanced platforms, with particular emphasis on scalability and supply chain localization. Awareness of these regional distinctions helps vendors and health systems tailor commercial strategies and implementation plans to local needs and regulatory realities.

A focused corporate insight outlining how suppliers are differentiating through platform innovation, service models, and strategic partnerships to win longevity and adoption

Competitive dynamics among companies operating in blood screening span platform innovation, reagent portfolios, service models, and regulatory engagement. Leading suppliers are differentiating through investments in automation, digital connectivity, and assay breadth to serve both high-throughput blood bank environments and decentralized point-of-care settings. These firms are also refining aftermarket offerings-including remote diagnostics support, consumable management, and training programs-to increase customer retention and reduce operational friction for end users.

Partnerships and co-development arrangements with clinical laboratories, academic centers, and manufacturing partners are increasingly common as companies seek to accelerate validation pathways and localize production. Strategic focus areas for market participants include improving turnaround times, reducing sample volume requirements, and enhancing multiplexing capabilities to consolidate testing workflows. Vendors that demonstrate clear evidence of clinical utility, operational reliability, and robust post-sales support are more likely to secure long-term procurement commitments from healthcare providers and blood services.

Concrete recommendations for executives to enhance diagnostic flexibility, supply resilience, digital integration, workforce readiness, and collaborative validation to future-proof screening programs

Industry leaders should prioritize a set of actionable measures that balance clinical excellence with operational resilience and commercial agility. First, embed modularity into procurement decisions by selecting platforms that allow incremental upgrades and multi-assay support to reduce long-term vendor lock-in and preserve flexibility as testing needs evolve. Second, invest in supply chain diversification and contractual clauses that protect against geopolitical and tariff-driven disruptions while ensuring continuity of critical consumables.

Third, accelerate integration of digital connectivity and laboratory information systems to improve result traceability, quality oversight, and interoperability across care settings. Fourth, develop clear adoption roadmaps that pair laboratory validation with staff training and confirmatory testing pathways so new technologies can be scaled without compromising safety. Finally, pursue collaborative pilot programs with public health agencies and donor organizations to validate novel testing protocols in real-world environments. These steps will help organizations manage risk, optimize operational performance, and sustain screening quality over time.

A transparent, tri-angulated research methodology combining stakeholder interviews, regulatory guidance review, and technology assessment to produce actionable insights for decision makers

This research synthesis draws on a triangulated methodology combining primary stakeholder interviews, protocol and regulatory guidance review, and systematic technology assessment to produce robust insights. Primary engagements included conversations with laboratory directors, transfusion medicine specialists, procurement leaders, and diagnostics vendors to surface practical constraints, adoption drivers, and implementation experiences. These qualitative inputs were supplemented by a structured review of public regulatory guidance, clinical validation reports, and device labeling to verify performance claims and pathway requirements.

Technology assessments evaluated analytical principles, operational characteristics, and interoperability features across platform types. Supply chain analysis examined manufacturing footprints, distribution channels, and tariff-sensitive procurement dependencies to understand risk vectors. Throughout the process, evidence was contextualized to reflect regional regulatory environments and typical end-user operational models. Findings were synthesized to emphasize actionable implications rather than abstract projections, and to support strategic decision-making for clinical, operational, and commercial stakeholders.

A clear and practical conclusion emphasizing evidence-driven adoption, supply chain resilience, and digital integration as the pillars of sustainable blood screening programs

Blood screening stands at the intersection of clinical necessity and technological possibility, requiring stakeholders to make disciplined choices that reconcile analytical performance with operational constraints. Emerging tools and enhanced connectivity offer opportunities to shorten detection windows, simplify workflows, and improve traceability, but successful adoption depends on tailored implementation strategies that reflect local infrastructure, staff competencies, and supply chain realities. Decision makers should therefore prioritize solutions that deliver both clinical value and operational viability.

In essence, the imperative is to adopt a pragmatic, evidence-driven approach: validate platforms within the context of intended use, strengthen supply chain governance to withstand policy shifts, and integrate digital workflows that support quality and interoperability. By doing so, healthcare organizations and diagnostic providers can ensure that blood screening systems are not only technologically advanced but also resilient, scalable, and closely aligned to patient safety objectives.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of AI-driven predictive analytics in blood disease screening workflows to improve detection accuracy
  • 5.2. Expansion of at-home blood screening kits leveraging smartphone connectivity and remote lab integration for personalized health monitoring
  • 5.3. Adoption of multiplex immunoassays for simultaneous detection of multiple blood markers enhancing diagnostic efficiency and throughput
  • 5.4. Rising demand for point-of-care blood screening devices in rural and underserved regions to facilitate early disease detection
  • 5.5. Development of next-generation sequencing panels for comprehensive blood-borne pathogen screening in transfusion services
  • 5.6. Regulatory shifts driving harmonization of blood screening standards across emerging markets to streamline global testing protocols

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Screening Market, by Test Type

  • 8.1. Hepatitis B Screening
  • 8.2. Hepatitis C Screening
  • 8.3. HIV Screening
  • 8.4. Syphilis Screening

9. Blood Screening Market, by Technology

  • 9.1. Chemiluminescence
  • 9.2. Flow Cytometry
  • 9.3. Immunoassays
    • 9.3.1. Chemiluminescence Immunoassay
    • 9.3.2. Enzyme Linked Immunosorbent Assay
    • 9.3.3. Radioimmunoassay
  • 9.4. Molecular Diagnostics
    • 9.4.1. Isothermal Amplification
    • 9.4.2. Next Generation Sequencing
    • 9.4.3. Polymerase Chain Reaction

10. Blood Screening Market, by End User

  • 10.1. Blood Banks
  • 10.2. Clinics
  • 10.3. Diagnostic Laboratories
  • 10.4. Hospitals

11. Blood Screening Market, by Sample Type

  • 11.1. Plasma
  • 11.2. Serum
  • 11.3. Whole Blood

12. Blood Screening Market, by Testing Mode

  • 12.1. Lab Based
  • 12.2. Point Of Care

13. Blood Screening Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Blood Screening Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Blood Screening Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. F. Hoffmann-La Roche Ltd
    • 16.3.2. Abbott Laboratories
    • 16.3.3. Siemens Healthineers AG
    • 16.3.4. Danaher Corporation
    • 16.3.5. Thermo Fisher Scientific Inc.
    • 16.3.6. Grifols, S.A.
    • 16.3.7. Bio-Rad Laboratories, Inc.
    • 16.3.8. Ortho Clinical Diagnostics, Inc.
    • 16.3.9. Hologic, Inc.
    • 16.3.10. Terumo BCT, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BLOOD SCREENING MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BLOOD SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BLOOD SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD SCREENING MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD SCREENING MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS B SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD SCREENING MARKET SIZE, BY HEPATITIS C SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD SCREENING MARKET SIZE, BY HIV SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD SCREENING MARKET SIZE, BY SYPHILIS SCREENING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD SCREENING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD SCREENING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD SCREENING MARKET SIZE, BY ENZYME LINKED IMMUNOSORBENT ASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD SCREENING MARKET SIZE, BY RADIOIMMUNOASSAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD SCREENING MARKET SIZE, BY ISOTHERMAL AMPLIFICATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD SCREENING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD SCREENING MARKET SIZE, BY BLOOD BANKS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD SCREENING MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD SCREENING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD SCREENING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLOOD SCREENING MARKET SIZE, BY PLASMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLOOD SCREENING MARKET SIZE, BY SERUM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BLOOD SCREENING MARKET SIZE, BY WHOLE BLOOD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BLOOD SCREENING MARKET SIZE, BY LAB BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BLOOD SCREENING MARKET SIZE, BY POINT OF CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 173. AMERICAS BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 174. AMERICAS BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 240. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 242. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 244. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 255. AFRICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. AFRICA BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. AFRICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. AFRICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. AFRICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. AFRICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. AFRICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 262. AFRICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 274. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 275. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 276. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 277. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 278. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 279. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 280. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL BLOOD SCREENING MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL BLOOD SCREENING MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. ASEAN BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. ASEAN BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. ASEAN BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASEAN BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. ASEAN BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. ASEAN BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 295. ASEAN BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 296. ASEAN BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 297. ASEAN BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 298. ASEAN BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 299. ASEAN BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 300. ASEAN BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 305. GCC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. GCC BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. GCC BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. GCC BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. GCC BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 310. GCC BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 311. GCC BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 312. GCC BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 313. GCC BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 314. GCC BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 315. GCC BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. GCC BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. GCC BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. GCC BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. GCC BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 320. GCC BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2024 (USD MILLION)
  • TABLE 336. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025-2032 (USD MILLION)
  • TABLE 337. BRICS BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 338. BRICS BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 339. BRICS BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 340. BRICS BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025-2032 (USD MILLION)
  • TABLE 341. BRICS BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 342. BRICS BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 343. BRICS BLOOD SCREENING MAR